News

FIRST-LINE LORLATINIB OR CRIZOTINIB IN ADVANCED ALK-POSITIVE LUNG CANCER

In a study published online in The New England Journal of Medicine, Alice T. Shaw and coauthors presented the results of CROWN, a phase III trial evaluating the third-generation tyrosine kinase inhibitor (TKI) lorlatinib in patients with advanced non–small cell lung cancer (NSCLC) harboring an ALK translocation.  ALK translocation and mutations occur in 2% to 7% …

FIRST-LINE LORLATINIB OR CRIZOTINIB IN ADVANCED ALK-POSITIVE LUNG CANCER Read More »

MUTANT IDH1 INHIBITOR IVOSIDENIB COMBINED WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

The authors of this phase Ib trial evaluated the oral IDH1 inhibitor ivosidenib in combination with azacitidine in 23 patients with newly diagnosed acute myeloid leukemia ineligible for intensive induction chemotherapy. The overall and complete response rates were 78% and 61%, respectively. The median duration of response and median overall survival were not yet reached …

MUTANT IDH1 INHIBITOR IVOSIDENIB COMBINED WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA Read More »

OLAPARIB FOR METASTATIC BREAST CANCER AND MUTATIONS IN HOMOLOGOUS RECOMBINATION–RELATED GENES

The authors of this phase II trial evaluated the PARP inhibitor olaparib in the treatment of 54 patients with metastatic breast cancer (76% ER-positive/HER2-negative) and either germline mutations in non-BRCA1/2 homologous recombination–related DNA repair genes (cohort 1) or somatic mutations in BRCA1/2 or other non-BRCA1/2 homologous recombination–related genes (cohort 2). The objective response rate (ORR) …

OLAPARIB FOR METASTATIC BREAST CANCER AND MUTATIONS IN HOMOLOGOUS RECOMBINATION–RELATED GENES Read More »

FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH LOCALLY RECURRENT UNRESECTABLE OR METASTATIC TRIPLE‑NEGATIVE BREAST CANCER WHOSE TUMORS EXPRESS PD-L1 (CPS ≥10)

The U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10). “Approximately 15-20% of patients with breast cancer are diagnosed with triple-negative breast cancer, which …

FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH LOCALLY RECURRENT UNRESECTABLE OR METASTATIC TRIPLE‑NEGATIVE BREAST CANCER WHOSE TUMORS EXPRESS PD-L1 (CPS ≥10) Read More »

FIVE-YEAR OUTCOMES WITH NIVOLUMAB IN PATIENTS WITH WILD-TYPE BRAF ADVANCED MELANOMA

The authors report the 5-year outcomes of this multicenter, double-blind, phase III study of nivolumab versus dacarbazine for the first-line treatment of 418 patients with unresectable stage III/IV, wild-type BRAF melanoma. Benefits for overall survival, progression-free survival, and objective response rate with nivolumab were confirmed. The 5-year overall survival rate was 39% with nivolumab. Among …

FIVE-YEAR OUTCOMES WITH NIVOLUMAB IN PATIENTS WITH WILD-TYPE BRAF ADVANCED MELANOMA Read More »

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA IN PATIENTS WITH HIGH-RISK CYTOGENETIC FACTORS

The authors of this review and meta-analysis of phase III trials evaluated the use of daratumumab for the treatment of newly diagnosed and relapsed/refractory multiple myeloma. While the individual trials did not demonstrate a statistically significant survival benefit, the meta-analysis did showed improvement in both progression-free and overall survival with daratumumab for both standard-risk and …

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA IN PATIENTS WITH HIGH-RISK CYTOGENETIC FACTORS Read More »

EFFICACY OF MAINTENANCE OLAPARIB FOR PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER WITH A BRCA MUTATION

Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has demonstrated efficacy in several tumor types, including advanced ovarian cancer, breast, prostate, and pancreatic cancers. Olaparib is approved in the United States, the European Union, and other countries as maintenance treatment for women with germline or somatic BRCA-mutated advanced OC who are in response to first-line platinum-based chemotherapy …

EFFICACY OF MAINTENANCE OLAPARIB FOR PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER WITH A BRCA MUTATION Read More »

IMPLICATIONS OF TP53 ALLELIC STATE FOR GENOME STABILITY, CLINICAL PRESENTATION AND OUTCOMES IN MYELODYSPLASTIC SYNDROMES

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer. In patients with myelodysplastic síndromes (MDS), TP53 mutations are associated with high-risk disease, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies and dismal outcomes. Consistent with the tumor-suppressive role of TP53, patients harbor both mono- and biallelic mutations. However, the …

IMPLICATIONS OF TP53 ALLELIC STATE FOR GENOME STABILITY, CLINICAL PRESENTATION AND OUTCOMES IN MYELODYSPLASTIC SYNDROMES Read More »

ASSOCIATION OF SPAG5 AND TREATMENT RESPONSE IN PATIENTS WITH ER-POSITIVE BREAST CANCER

Sperm-associated antigen 5 (SPAG5) represents a novel oncogene in estrogen receptor (ER)–positive luminal-B breast cancer. The authors of this study evaluated the association of SPAG5 gene and protein expression and treatment response in 12,270 patients with ER-positive breast cancer. Overexpression was associated with higher odds of a pathologic complete response. Furthermore, among women with SPAG …

ASSOCIATION OF SPAG5 AND TREATMENT RESPONSE IN PATIENTS WITH ER-POSITIVE BREAST CANCER Read More »

GENOMIC PROFILING OF SMOLDERING MULTIPLE MYELOMA IDENTIFIES PATIENTS AT A HIGH RISK OF DISEASE PROGRESSION

Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The discovery of genomic alterations that underlie disease progression to MM could improve current risk models. We observed that most of …

GENOMIC PROFILING OF SMOLDERING MULTIPLE MYELOMA IDENTIFIES PATIENTS AT A HIGH RISK OF DISEASE PROGRESSION Read More »